Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22

BACKGROUND: Irrespective of the first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key consideration when assessing therapeutic choices is the availability of subsequent treatment options following disease p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hyun Ae, Hong, Min Hee, Lee, Hyun Woo, Lee, Kyung Hee, Kim, Il Hwan, Min, Young Joo, Ahn, Hee Kyung, Shim, Byoung Yong, Choi, Yoon Hee, Lee, Yun-Gyoo, Kim, Jeong A, Jang, Joung Soon, Shin, Seong-Hoon, Park, Keon Uk, Kang, Jin Hyoung, Park, Keunchil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359965/
https://www.ncbi.nlm.nih.gov/pubmed/35958320
http://dx.doi.org/10.21037/tlcr-22-79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359965/
https://www.ncbi.nlm.nih.gov/pubmed/35958320
http://dx.doi.org/10.21037/tlcr-22-79

Ejemplares similares